The PARPscore System Using Poly (ADP-ribose) Polymerase (PARP) Family Features and Tumor Immune Microenvironment in Glioma

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 26

PMID 39724285

Authors

Cheng Zhang

Juan Feng

Xia Zhou

Jie Zhang

Chuming Tao

Hongwei Zhou

Affiliations

Soon will be listed here.

Abstract

The immune response plays a pivotal role in tumor progression and therapy. However, the influence of protein PAR polymerases (PARPs) modifications on cell infiltration within the tumor microenvironment (TME) remains insufficiently understood. In this study, the Clinical and RNA sequencing data we performed a comprehensive analysis of PARPs modification patterns, exploring their associations with TME cell infiltration were acquired from the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) database. To quantify PARPs modification in individual tumors, we developed a novel metric, the PARPscore, derived using principal component analysis. Our findings revealed three distinct PARPs modification patterns, each correlated with unique TME infiltration characteristics and tumor immunophenotypes. These patterns demonstrated predictive value for various clinical parameters, including inflammation stage, tumor subtypes, TME matrix activity, genetic variations, and patient prognosis. Notably, the high PARPscore subtype exhibited features of stromal activation and reduced immune infiltration, indicative of a non-inflamed, immune-excluded TME phenotype, and was associated with poorer survival outcomes. Conversely, lower PARPscore subtypes corresponded to substantial therapeutic benefits and improved outcomes in two independent immunotherapy cohorts. This study underscores the critical role of PARPs modification in shaping the diverse and dynamic TME. By delineating tumor-specific PARPs modification patterns, we provide valuable insights into TME complexity and its implications for immunotherapy.

References

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Rosado M, Pioli C . ADP-ribosylation in evasion, promotion and exacerbation of immune responses. Immunology. 2021; 164(1):15-30. PMC: 8358716. DOI: 10.1111/imm.13332. View

Jensen O . Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol. 2006; 7(6):391-403. DOI: 10.1038/nrm1939. View

Chuntova P, Chow F, Watchmaker P, Galvez M, Heimberger A, Newell E . Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2020; 23(3):356-375. PMC: 7992879. DOI: 10.1093/neuonc/noaa277. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Joyce J, Fearon D . T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015; 348(6230):74-80. DOI: 10.1126/science.aaa6204. View

Rey-Cardenas M, Guerrero-Ramos F, Gomez de Liano Lista A, Carretero-Gonzalez A, Bote H, Herrera-Juarez M . Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Cancer Treat Rev. 2021; 93:102142. DOI: 10.1016/j.ctrv.2020.102142. View

Palazzo L, Mikolcevic P, Mikoc A, Ahel I . ADP-ribosylation signalling and human disease. Open Biol. 2019; 9(4):190041. PMC: 6501648. DOI: 10.1098/rsob.190041. View

10.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

11.

Sim H, Galanis E, Khasraw M . PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers (Basel). 2022; 14(4). PMC: 8869934. DOI: 10.3390/cancers14041003. View

12.

Zhang N, Zhang L, Qiu B, Meng L, Wang X, Hou B . Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas. J Magn Reson Imaging. 2012; 36(2):355-63. PMC: 3399966. DOI: 10.1002/jmri.23675. View

13.

Gibson B, Kraus W . New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012; 13(7):411-24. DOI: 10.1038/nrm3376. View

14.

Zhu H, Tang Y, Zhan G, Su C, Zheng C . The Critical Role of PARPs in Regulating Innate Immune Responses. Front Immunol. 2021; 12:712556. PMC: 8341640. DOI: 10.3389/fimmu.2021.712556. View

15.

Daniels C, Ong S, Leung A . The Promise of Proteomics for the Study of ADP-Ribosylation. Mol Cell. 2015; 58(6):911-24. PMC: 4486045. DOI: 10.1016/j.molcel.2015.06.012. View

16.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

17.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

18.

Jia Q, Wu W, Wang Y, Alexander P, Sun C, Gong Z . Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018; 9(1):5361. PMC: 6299138. DOI: 10.1038/s41467-018-07767-w. View

19.

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou Y . mA regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020; 19(1):53. PMC: 7066851. DOI: 10.1186/s12943-020-01170-0. View

20.

Peyraud F, Italiano A . Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers (Basel). 2020; 12(6). PMC: 7352466. DOI: 10.3390/cancers12061502. View